|
    ADGI U.S.: Nasdaq

    Adagio Therapeutics Inc.

    ADGIUS
    After Hours
    Last Updated: Jan 20, 2022 7:59 p.m. EST Delayed quote

    $ 6.41

    -0.03 -0.47%
    After Hours Volume: 262.13K
    Close Chg Chg %
    $6.44 0.89 16.04%
    Advanced Charting
    Volume: 9.38M 65 Day Avg: 7.79M
    120% vs Avg
    5.61 Day Range 6.99
    4.92 52 Week Range 78.82

    Your Watchlists

    Customize eLesor

    Have Watchlists? Log in to see them here or sign up to get started.

    Symbol
    Company
    Price
    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    Uh oh

    Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    ADGI Overview

    Performance

    5 Day
    • 22.43%
    1 Month
    • -25.64%
    3 Month
    • -80.86%
    YTD
    • -11.29%

    Analyst Ratings

    • Sell
    • Under
    • Hold
    • Over
    • Buy
    Number of Ratings 4 Full Ratings

    Recent News

    Adagio Therapeutics Up 21%

    Adagio Therapeutics Shares Rise Premarket on ADG20 Omicron Update >ADGI

    Adagio Therapeutics Details Omicron-Related Efforts

    Adagio Therapeutics downgraded to underweight at Morgan Stanley

    Adagio Therapeutics Continue to Slide After Omicron Findings

    Adagio Therapeutics downgraded to hold from buy at Stifel, price target slashed to $9 from $50

    Read full story

    Adagio Backtracks, Says Lab Data Show Its Antibody Won’t Work Against Omicron

    Adagio Therapeutics Shares Down Sharply After Omicron Findings

    Read full story

    FDA Authorizes AstraZeneca Drug to Prevent Covid. It’s an Alternative to Vaccines for Some.

    Read full story

    Regeneron Stock Is Falling Because Its Covid Antibody Might Not Work as Well Against Omicron

    Adagio Therapeutics Shares Rise 69% on Covid-19 Antibody, Omicron Variant

    Adagio Therapeutics upgraded to overweight at Morgan Stanley

    Read full story

    Premarket Movers: Adagio Therapeutics, Wynn Resorts, Squarespace

    Read full story

    DoubleDown Interactive Shares Drop Below IPO Price

    Adagio Therapeutics started at buy with $57 stock price target at Stifel Nicolaus

    Read full story

    The IPO Market Is on Break. Adagio Is Friday’s Only Deal.

    Adagio Therapeutics' upsized IPO prices in middle of range, valued company at more than $1.8 billion

    Adagio Therapeutics sets IPO terms, looks to raise up to $318.6 million

    Adagio Therapeutics sets IPO terms, to be valued at up to $1.8 bln

    Why Shares of Adagio Therapeutics Soared 25.9% on Thursday

    on Motley Fool

    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

    on InvestorPlace.com

    Adagio Reveals Promising Data on ADG20 Against Omicron; Shares Surge

    on TipRanks.com

    Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ...

    on GuruFocus.com

    Why Adagio Therapeutics Stock Dived by 13% Today

    on Motley Fool

    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

    on InvestorPlace.com

    Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ...

    on GuruFocus.com

    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

    on InvestorPlace.com

    ADGI Stock Alert: 4 Things to Know as Adagio Therapeutics Rockets 100%

    on InvestorPlace.com

    Why Adagio Therapeutics Stock Is Falling Again Today

    on Motley Fool

    Adagio: Omicron Wins Against Treatment; Shares Slashed

    on TipRanks.com

    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

    on InvestorPlace.com

    ADGI Stock Alert: The Omicron Variant Just Sent Adagio Therapeutics Plunging

    on InvestorPlace.com

    Why Adagio Therapeutics Stock Is Crashing Today

    on Motley Fool

    3 Beaten-Down Biotech Stocks -- Are They Bargains Now?

    on Motley Fool

    Will Adagio's COVID Antibody Therapy Be Too Late to the Party?

    on Motley Fool

    4 Pharma Stocks Poised to Benefit from Omicron Variant Scare

    on TipRanks.com

    Company News for Nov 30, 2021

    on Zacks.com

    ArrowMark Colorado Holdings LLC Buys Adagio Therapeutics Inc, N-able Inc, Momentive Global Inc, ...

    on GuruFocus.com

    Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ...

    on GuruFocus.com

    Adagio Therapeutics Inc.

    Adagio Therapeutics, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren? Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.